Carnitine palmitoyltransferase
From Proteopedia
| Line 15: | Line 15: | ||
[[2fw3]] - rCPT II + antidiabetic drug<br /> | [[2fw3]] - rCPT II + antidiabetic drug<br /> | ||
[[2rcu]] – rCPT II + substrate analog<br /> | [[2rcu]] – rCPT II + substrate analog<br /> | ||
| + | [[4ep9]], [[4eph]], [[4eyw]] - rCPT II + inhibitor<br /> | ||
[[2le3]] – CPT I residues 1-42 – human - NMR | [[2le3]] – CPT I residues 1-42 – human - NMR | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 10:01, 4 December 2013
Carnitine palmitoyltransferase (CPT I and CPT II) are involved in the transport of long-chain fatty acids into the mitochondria where they are oxidized. Fatty acids form a conjugate with CoA before being oxidized in the mitochondria. However, the CoA-long-chain fatty acid conjugates can not diffuse into the mitochondria. CPT I is a membrane protein which substitutes the CoA in the long-chain fatty acids by carnitine. After entering the mitochondria, CPT II exchanges the carnitine by CoA, enabling the oxidation of the long-chain fatty acids. CPT I is important in fatty acid disorders like diabetes.
3D structures of carnitine palmitoyltransferase
Updated on 04-December-2013
2h4t, 2fyo, 2deb – rCPT II – rat
2fw3 - rCPT II + antidiabetic drug
2rcu – rCPT II + substrate analog
4ep9, 4eph, 4eyw - rCPT II + inhibitor
2le3 – CPT I residues 1-42 – human - NMR
